3rd Quarter - Report

VIATRIS INC. for VIATRIS INC

Firm
Client
Income
—
Expenses
$590,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Issues related Inter Partes Review (IPR) process for biosimilars and generic drugs S.344, H.R. 990 - Hatch-Waxman Integrity Act of 2019 Patent Settlements

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
AKSHAI DATTA —
DAVID MARIN —
PETER WALLACE —

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; White House Office

Bills named: S. 344 (116th), H.R. 990 (116th)

Budget/Appropriations BUD

Medicaid Rebate provision of the Bipartisan Budget Act of 2015

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —
ANNE WILSON —

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS); White House Office; HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

Trade issues related to generic medicines Access to global pharmaceutical supply chain and incentives for domestic manufacturing

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —
ANNE WILSON —

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); White House Office

Financial Institutions/Investments/Securities FIN

Policy related to corporate governance

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
DAVID MARIN —

Contacted: White House Office; Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Taxation/Internal Revenue Code TAX

H.R. 6930 - Made in America Act Tax incentives for domestic manufacturing

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —
ANNE WILSON —

Contacted: Health & Human Services, Dept of (HHS); SENATE; White House Office; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 6930 (116th)

Health Issues HCR

Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Generic drug quality and FDA oversight Medicare reimbursement for biosimilars, shared savings for Part B providers S.2543 - Prescription Drug Pricing Reduction Act S. 1416 - Affordable Prescriptions for Patients Act S. 1895 - Lower Health Care Costs Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R. 938 - BLOCKING Act of 2019 H.R. 1499 - The Protecting Consumer Access to Generic Drugs Act of 2019 Part D Formulary Design and Generic Drug Tiering H.R. 4913 - Ensuring Access to Lower-Cost Medicines for Seniors Act H.R. 4455 - BIOSIM Act H.R. 4629 - Star Rating for Biosimilars Act H.R. 6179 - Increasing Access to Biosimilars Act of 2020 S. 2723 - Mitigating Emergency Drug Shortages Act H.R. 5304 - PBM Transparency in Prescription Drug Costs Act H.R. 748 - CARES Act H.R. 6431 - Made in America Emergency Preparedness Act S. 4134, Increasing Access to Biosimilars Act of 2020 Electronic Labeling of Prescription Drugs

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —
ANNE WILSON —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; White House Office; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS)

Bills named: S. 1416 (116th), S. 2543 (116th), H.R. 5304 (116th), S. 4134 (116th), S. 2723 (116th), H.R. 3 (116th), S. 1895 (116th), H.R. 6431 (116th), H.R. 748 (116th), H.R. 4455 (116th), H.R. 4913 (116th), H.R. 938 (116th), H.R. 6179 (116th), H.R. 1499 (116th), H.R. 4629 (116th)

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
MYLAN NV United Kingdom United Kingdom 100.0% —
MYLAN HOLDINGS LIMITED United Kingdom United Kingdom 100.0% —

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.